Index

A
Activated protein C (APC), 32, 133, 137–140
Acute Dialysis Quality Initiative (ADQI), 99
Acute kidney injury (AKI). See also Acute renal failure (ARF)
definition and stratification
AKIN classification, 100
glomerular filtration rate (GFR), 99
RIFLE classification, 99–100
diagnosis and monitoring
conventional biomarkers, 100
GFR and Cr, relationship, 101
management, 106
monitoring and diagnostic tests
blood urea nitrogen (BUN), 102
diagnostic algorithm, 103
renal biopsy, 103
sodium fractional excretion, 103
ultrasonography (US), 102
new biomarkers, 101–102
prevention
contrast-induced nephropathy risk score, 105
contrast related nephrotoxicity (CRN), 106
intraabdominal hypertension (IAH), 104
ischemic renal failure, 103
other preventive actions, 106
prerenal disease and renal ischemic damage, differences, 103
pulmonary artery catheter (PAC), 104
toxic renal failure, 104–106
sepsis, 98
Acute kidney injury network (AKIN), 100
Acute Physiology and Chronic Health Evaluation (APACHE) II score, 59, 60
Acute renal failure (ARF), 55, 59, 97–101, 106, 110
Acute renal injury, extracorporeal blood purification
AKI and sepsis, 98
AKI prevention, 103–106
definition and stratification, 98–100
diagnosis and monitoring, 100–103
management, 106–112
Acute respiratory distress syndrome (ARDS), 7, 33, 34, 56, 59
Acute tubular necrosis (ATN), 97, 103
Adjunctive therapy, 61
ADQI. See Acute Dialysis Quality Initiative
AKIN. See Acute kidney injury network
American College of Chest Physicians (ACCP), 11
American Thoracic Society (ATS), 54, 59
Antibiotics
clindamycin, 27
combination, 27–28
macrolides, 27, 28
penicillin, 26, 27
severe sepsis
clinical practice implications, 155
epidemiology and microbiology, 147–148
methicillin-resistant Staphylococcus aureus, 153–154
monotherapy vs. combination therapy, 151–153
resistance development, 148–149
treatment, 149–151, 154–155
Antimicrobial therapy
delay, 66–67
fluorescence in situ hybridization (FISH), 68
hybridization approach, 67, 70, 78
limitations, 77
Antithrombin (AT), 133, 136–137
APACHE. See Acute Physiology and Chronic Health Evaluation
APC. See Activated protein C
Appropriate antibiotic treatment, 59
Appropriateness of initial empirical antibiotic therapy, 43
ARDS. See Acute respiratory distress syndrome
ATN. See Acute tubular necrosis
ATS. See American Thoracic Society

B
Bacteremia, 27–28, 30, 52, 55–57
Biomarkers, 43, 55, 59
C-reactive protein, 43
procalcitonin, 43
Blood culture, 66–72, 74–78
Bloodstream infections (BSIs), 66

C
Cancer, 2–3, 7–8
Candida, 7
CAP PIRO score, 55–61
Chronic obstructive pulmonary disease (COPD), 52, 53, 55, 57
corticosteroids, 25
Community-acquired pneumonia (CAP) bacteremic pneumococcal pneumonia, 58 pneumococcal bacteremic pneumonia, 53 severe CAP, 51, 52, 55–60
Comorbidities, 52, 55–57
Confusion, urea, respiratory rate, blood pressure, age ≥65 years (CURB-65), 53, 54
Continuous hemodiafiltration, 34
Continuous renal replacement therapy (CRRT), 107, 108, 110, 111
Contrast-related nephrotoxicity (CRN), 106
COPD. See Chronic obstructive pulmonary disease
Cortisol, 59
C-reactive protein (CRP), 1, 59
CRP. See C-reactive protein
CRRT. See Continuous renal replacement therapy
CURB-65. See Confusion, urea, respiratory rate, blood pressure, age ≥65 years
Cytokines, 59

D
28-Day mortality, 59
Disseminated intravascular coagulation (DIC), 131–132, 134, 136, 138, 140

E
Early goal-directed therapy, 32–33
Endothelial protein C receptor (EPCR), 133, 137–138, 140
Escherichia (E.) coli, 134
Extracorporeal purification treatments (EPT), 107, 108, 110, 111

F
Fibrinolysis, 113, 138

G
Genetic, 24–25
CD14, 25
TLR, 25
tumor necrosis factor (TNF), 25
Glomerular filtration rate (GFR), 99, 100, 102, 104
Granulocyte colony-stimulating factor (G-CSF), 29, 30

H
Heparin, 136–137
Host response, 40, 43, 55, 58, 59 acute renal failure, 43 shock, 43 systolic blood pressure, 43
Hypoxemia, 29, 55, 58

I
ICU. See Intensive Care Unit; Intensive care units
IDSA. See Infectious diseases Society of America
Immune Response, 3–6
Immunity, 117–118, 120, 122–123
Immunization, 57
Immunocompromise, 55–57, 60
Immunoglobulin(s), 118, 120, 123–126
Immunosuppression, 52
Infection, 1–5, 7
Infectious Diseases Society of America (IDSA), 54
Index

Inflammation, 55, 58
Insult, 55, 57–58
Insult/infection, 40, 42–43
   *Acinetobacter baumannii*, 42
   bacteremia, 42
   early-onset VAP, 42
   high-risk microorganisms, 42
   late-onset VAP, 42
   microorganism virulence, 42
   MRSA, 43
   *Pseudomonas aeruginosa*, 42
Intensive care units (ICUs), 11, 39–44
Intensive respiratory and hemodynamic support, 58
Intravenous immunoglobulins (IVIC), 28

L
Lipopolysaccharide (LPS), 134–140
Logistic organ dysfunction (LOD) system, 13
Lower respiratory tract infection, 40

M
Macrolides, 58
Mechanical ventilation, 52, 54, 57, 60
Methicillin-resistant *Staphylococcus aureus* (MRSA), 71
Microparticles (MPs), 132, 134–135
MODS. See Multiple organ dysfunction/failure syndrome
Mortality, 40–47, 51–53, 57–60
Multiple organ dysfunction, 51
Multiple organ dysfunction/failure scores
   logical boxes, 14
   multivariate analysis, 15
   simplified acute physiology score (SAPS), 14
   systemic inflammatory response syndrome (SIRS), 14
   Multiple organ dysfunction/failure syndrome (MODS), 12

N
Noninvasive Mechanical Ventilation (NIMV), 33
Nosocomial infection, 39, 40

O
Older patients, 57
One PIRO or many PIROs, 15–18
computation scoresheet, 16–18
ventilator-associated pneumonia (VAP-PIRO), 15
Organ dysfunction, 1–4, 6–7, 39, 40, 44, 51, 55, 59
ARDS, 43
Organ dysfunction/failure scores, 12–14
logistic organ dysfunction (LOD) system, 12
pressure-adjusted heart rate or PAR, 13
Organ failure, 59–60

P
PAC. See Pulmonary artery catheter
PAI-1. See Plasminogen activator inhibitor type-1
Panton-Valentine leukocidin, 58
PAR. See Pressure-adjusted heart rate; Protease-activated receptor
Pathogenesis, 58
PCR. See Polymerase chain reaction
PC. See Protein C
PIRO, 23–34, 39–47
   concept, 55, 57
PIRO/MODS scores
   nosocomial vs. community-acquired infection, 18–19
   surviving sepsis campaign, 18
Plasminogen activator inhibitor type-1 (PAI-1), 133, 138–139
Platelets, 135
Pneumococcal conjugated vaccine effectiveness, 89, 90
   herd immunity effect, 89, 94
   replacement phenomenon, 90, 95
Pneumococcal polysaccharide vaccine immunological response, 88, 90
   revaccination, 89
Pneumonia, 119–123, 125
   Pneumonia severity index (PSI), 53, 54, 60
Polymerase chain reaction (PCR), broad range, 70
Predisposition, 3–4, 7, 40–42, 44, 55–57
   age, 41, 42
   chronic heart failure, 41
   chronic hepatopathy, 41, 42
   Chronic obstructive pulmonary disease (COPD), 41
   immune system deficiency, 41
   trauma, 41
   Pressure-adjusted heart rate (PAR), 13
Prevention, 23, 24
  immunization, 24
  nutrition, 24
  smoking, 25
  vaccination, 23, 25, 26
Procalcitonin, 1, 5, 59
Protease-activated receptors (PARs), 132, 139–140
Protein C (PC), 132, 137–138
PSI. See Pneumonia severity index
Pulmonary artery catheter (PAC), 104

Q
Quantitative real-time polymerase chain reaction, 58

R
Radiological infiltrates, 58
Real time PCR
  available systems, 75–76
  contamination, 74–75
  interpretation, 77–78
  limitations, 78
  pathogene discrimination, 70
Renal replacement therapies
  acute renal failure
    continuous renal replacement therapy (CRRT), 107
    continuous venovenous hemodiafiltration (CVVHF), 109
dialytrauma, 110
dynamic approach to extracorporeal purification treatments, 109
slow low-efficient daily dialysis (SLEDD), 108
sepsis and MODS
  controversial aspects, HVHF, 112
  mean arterial pressure (MAP), 110
  putative mechanisms, 111–112
Resolution, 43
Response, 55, 58–59

S
SAPS. See Simplified acute physiology score
SCCM. See Society of Critical Care Medicine Score, 39–47
  Acute Physiology and Chronic Health Evaluation (APACHE II), 39–44
  multiple organ dysfunction score (MODS), 39
  organ dysfunction and infection score (ODIN), 39
  sequential organ failure assessment (SOFA), 39
  simplified acute physiology score (SAPS), 39
Sepsis, 117, 119–120, 125–126
  severe sepsis, 51, 52, 55, 58
Sepsis-related organ failure assessment (SOFA), 13, 14
Septic shock, 51, 52, 54, 55, 57, 58
Sequential organ failure assessment (SOFA), 6
Severe CAP, 51, 52, 55–60
Severe sepsis, risk stratification
  multiple organ dysfunction/failure scores, 14–15
  one PIRO or many PIROs, 15–18
  organ dysfunction/failure scores, 12–14
  PIRO/MODS scores, 18–19
Sex, 3, 4
Shock, refractory, 59
Simplified acute physiology score (SAPS), 14, 15, 18, 19
SIRS. See Systemic inflammatory response syndrome
SMART-COP, 54, 55
Society of Critical Care Medicine (SCCM), 11
SOFA score, 59
SOFA. See Sequential organ failure assessment; Sepsis-related organ failure assessment
Staphylococcus aureus, MRSA, 58
Steroids, 59
Streptococcus pneumoniae, 68, 71, 73
  clinical differences, 91–94
  DNA, 58
  high invasive disease potential, 92–93
  immunization, 88–91
  low invasive disease potential, 93–94
  mortality, 87, 91–94
  pediatric serotypes, 91
  polysaccharide capsule, 87
  serotypes, 87–95
Systemic inflammatory response syndrome (SIRS), 1, 14, 65, 76
Systemic vascular resistance (SVR), 1

T
Thrombin, 132–137, 139–140
Thrombomodulin (TM), 133, 137
Tissue factor pathway inhibitor (TFPI), 133, 136
Tissue factor (TF), 132–134, 136
Tumor, lymph nodes, metastasis (TNM), 23
Tumor necrosis factor (TNF), 4
Tumor necrosis factor-α (TNF-α), 133, 134

V
Ventilator-associated pneumonia (VAP), 7, 15, 39
Ventilator-associated pneumonia PIRO score (VAP PIRO), 39–47
comorbidities, 44
von Willebrand factor (vWF), 133, 135